BECKLEY CANOPY is a biopharmaceutical company designed to research and develop innovative cannabis-based health products, with a strict focus on intellectual property protection.
A collaborative joint venture, Beckley Canopy represents a partnership between world-renowned drug researcher Lady Amanda Feilding, Founder and Director of the Beckley Foundation, with Canadian cannabis pioneers Canopy Health Innovations.
20+ year track-record of pioneering research into the medical potential of psychoactive substances such as cannabis
Unparalleled network of world-class scientists and institutional collaborators, including Johns Hopkins, Imperial College London, UCL, Exeter University
Global leadership in drug policy and regulatory reform, advising the UN and governments around the world
Privileged access to research opportunities: e.g. Beckley Canopy’s first IP-generating study looking at a major indication
Strategic support from the most successful cannabis operation in the world and global leader in technology, licensing, and access to international cannabis markets
Unmatched management expertise and track record of success in both the cannabis and biopharmaceutical industries
Infrastructures and federal licences to grow, extract, and formulate pharmaceutical-quality cannabis products for clinical development, with over 1 million square feet of production capacity
Licensing and commercialization opportunities for products and IP developed by Beckley Canopy20+ year track-record of pioneering research into the medical potential of psychoactive substances such as cannabis
Staying true to both organizations’ commitment to corporate social responsibility, BECKLEY CANOPY will donate a share of all profits flowing from the collaborative research to support the not-for-profit drug policy and research work of the BECKLEY FOUNDATION.